Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions

Annals of Pharmacotherapy

Volumn 32, Issue 7-8, 1998, Pages 785-793

  Rapp, Robert P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Azalide antibiotics; Azithromycin; Macrolide antibiotics; Pharmacokinetics

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; MIDAZOLAM; RIFABUTIN; RIFAMPICIN; TERFENADINE; THEOPHYLLINE;

BACTERIAL INFECTION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0031873252     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17299     Document Type: Review

References (58)

1. Haight TH, Finland M. Observations on mode of action of erythromycin. Proc Soc Exp Biol Med 1952;81:188-93.
2. Washington JA II, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin Proc 1985;60: 189-203.
3. Prokesch RC, Hand WL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982;21:373-80.
4. Erythromycin. In: Kucers A, Bennett N McK, eds. The use of antibiotics. Philadelphia: JB Lippincott, 1987:851.
5. Edelstein PH, Meyer RD. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother 1980;18: 403-8.
6. Thacker SB, Bennett JV, Tsai T, Fraser DW, McDade JE, Shepard CC, et al. An outbreak in 1965 of severe respiratory illness caused by the Legionnaires' disease bacterium. J Infect Dis 1978;138:512-9.
7. Vildé J-L, Dournon E, Rajagopalan P. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother 1986;30:743-8.
8. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 1984;26: 863-9.
9. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992;33: 397-401.
10. Marlin GE, Thompson PJ, Jenkins CR, Burgess KR, La Franier DA. Study of serum levels, venous irritation, and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Hum Toxicol 1983;2:593-605.
11. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
12. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996;40:2577-81.
13. Olsen KM, San Pedro G, Gann LP, Gubbins PO, Halinski DM, Campbell GD Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40:2582-5.
14. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
15. Donowitz GR. Tissue-directed antibiotics and intracellular parasites: complex interaction of phagocytes, pathogens, and drugs. Clin Infect Dis 1994;19:926-30.
16. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 (suppl A):73-82.
17. Package insert. Zithromax (azithromycin capsules; azithromycin tablets; azithromycin for oral suspension; and azithromycin for injection). New York: Pfizer Laboratories, 1997.
18. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-5.
19. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26:1253-61.
20. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992;11:137-52.
21. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-9.
22. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148: 1418-26.
23. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995;14:669-76.
24. National Committee for Clinical Laboratory Standards. Table 2E, MIC interpretive standards (μg/mL) for Haemophilus spp. 1998:64-5.
25. National Committee for Clinical Laboratory Standards. Table 2G, MIC interpretive standards (μg/mL) for Streptococcus pneumoniae. 1998:68-9.
26. National Committee for Clinical Laboratory Standards. Table 2C, MIC interpretive standards (μg/mL) for Staphylococcus spp. 1998:56-9.
27. Thompson SE, Washington AE. Epidemiology of sexually transmitted Chlamydia trachomatis infections. Epidemiol Rev 1983;5:96-123.
28. Cassell GH, Cole BC. Mycoplasmas as agents of human disease. N Engl J Med 1981;304:80-9.
29. McDade JE, Shepard CC, Fraser DW, Tsai TR, Redus MA, Dowdle WR. Legionnaires' disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med 1977;297:1197-203.
30. Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 1996;40:75-9.
31. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370-4.
32. Pruul H, McDonald PJ. Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. Antimicrob Agents Chemother 1992;36:10-6.
33. Pruul H, McDonald PJ. Potentiation of azithromycin activity against Escherichia coli by human serum ultrafiltrate. J Antimicrob Chemother 1992;30:497-507.
34. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34: 1056-60.
35. Foulds G, Chan KH, Johnson JT, Shepard RM, Johnson RB. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991;10:853-6.
36. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeyboume D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990;3:886-90.
37. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother 1996;37(suppl C):93-101.
38. Vaudaux BP, Cherpillod J, Dayer P. Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996;37(suppl C):45-51.
39. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother 1996;37(suppl C):63-9.
40. Montera L. A comparative study of the efficacy, safety, and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother 1996;37(suppl C):125-31.
41. O'Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):71-81.
42. Zachariah J. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithmmycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):103-13.
43. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1996;37(suppl C):115-24.
44. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintilianie R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
45. Carlier MB, Scorneaux B, Tulkens PM. Accumulation, subcellular distribution and activity of azithromycin (Az) compared to roxithromycin (Rx) and ciprofloxacin (Cp) in J774 macrophages (Mo) (abstract). 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991.
46. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(suppl 3A):5S-11S.
47. Frank MO, Sullivan GW, Carper HT, Mandell GL. In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. Antimicrob Agents Chemother 1992;36:2584-8.
48. Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother 1996;37(suppl C):9-19.
49. Retsema J, Bergeron J, Girard D, Milisen WB. Preferential concentration of azithromycin in infected mouse thighs as compared to contralateral non-infected thighs (abstract). 91st General Meeting of the American Society for Microbiology, 1991.
50. Tissi L, von Hunolstein C, Mosci P, Campanelli C, Bistoni F, Orefici G. In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Antimicrob Agents Chemother 1995;39:1938-47.
51. Girard D, Regan PA, Milisen WB, Retsema JA, Swindell AC. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. J Antimicrob Chemother 1996;37(suppl C):21-35.
52. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-17.
53. Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Therapeut 1996;18:56-72.
54. Olkkola KT, Aranko K, Luurila H, Hiller A, Saamivaara L, Himberg J-J, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
55. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Therapeut 1996;34:400-5.
56. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
57. Honig P, Wortham D, Zamini K, Conner D, Cantilena L. Effect of erythromycin, clarithromycin, and azithromycin on the pharmacokinetics of terfenadine (abstract). Clin Pharmacol Ther 1993;53:161.
58. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(suppl 3A):40S-5S.